Translate this page into:
Tc99m sulfur colloid scintigraphy in differentiating noncirrhotic portal fibrosis from cirrhosis liver
Address for correspondence: Prof. Viroj Wiwanitkit, Wiwanitkit House, Bangkhae, Bangkok 10330, Thailand. E-mail: wviroj@yahoo.com
This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This article was originally published by Medknow Publications & Media Pvt Ltd and was migrated to Scientific Scholar after the change of Publisher.
Sir,
I read the recent publication on ‘Tc99m sulfur colloid scintigraphy in differentiating non-cirrhotic portal fibrosis (NCPF) from cirrhosis liver’ with great interest.[1] Chakraborty et al., concluded that “Tc99m sulfur colloid liver scan is a non-invasive procedure having a useful adjunctive role in clinical differentiation of cirrhosis from NCPF.”[1] Based on the findings, I agree with the authors. However, I would like to share some facts on technetium-99m (Tc99m). The problem with some conditions that mimic the results of Tc99m is reported.[2] The complementary use of chest X-ray is suggested.[3] Although this is not a common case, it should be noted and kept in mind.
REFERENCES
- Role of Tc99m sulfur colloid scintigraphy in differentiating non-cirrhotic portal fibrosis from cirrhosis liver. Indian J Nucl Med. 2010;25:139-42.
- [Google Scholar]
- Hydronephrosis mimicking metastatic disease on a Tc-99m sulfur colloid liver/spleen scan. Clin Nucl Med. 1983;8:225-6.
- [Google Scholar]
- Complementary role of chest roentgenogram in interpretation of Tc-99m sulfur colloid liver scan. Clin Nucl Med. 1984;9:460-2.
- [Google Scholar]